If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Renalytix AI plc (RNLX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. KidneyIntelX, their first-in-class diagnostic platform, employs a proprietary AI-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (EHR) systems, to generate a unique patient risk score, which. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians to optimize the allocation of treatments and clinical resources to patients at highest risk. CKD affects approximately 37 million individuals in the US, significantly impacting their quality of life and resulting in Medicare spending of over $120 billion per year. They believe they are well-positioned to help meet an urgent medical need with KidneyIntelX, a laboratory developed test (LDT) which has been granted a common procedural terminology (CPT) code, national Medicare pricing, and a positive coverage determination from a regional, private physician-led health insurance payor. Further, it has been granted breakthrough device designation from the U.S. FDA. Building on these milestones, they believe their population health-based business model, which includes partnerships with healthcare systems such as Mount Sinai Health System, will help facilitate commercial adoption of KidneyIntelX in the US.
James McCullough O. James Sterling
Employees Founded
14 2018


Address: Avon House 19 Stanwell Road Penarth, Cardiff CF64 2EZ United Kingdom

Telephone: +44 20 3139 2910

Web page:

IPO information

Expected Date 7/17/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $0
Net Income (Loss) (MM) $-9.0


What do you think will happen with the RNLX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 5.5
Shares Revised (MM) 5.5
Expected offer amount (MM) $78.21
Realized offer amount(MM) $74.25
JP Morgan/ Stifel

Sector: Healthcare

Tweets about $RNLX

Tweets volume:

RT volume:


Google Trends Stats